



# Veterinary Medicines Products Shortages state of play and management in France


## HMA/EMA multi-stakeholder workshop on shortages - veterinary break-out session

ANMV - Paule Carnat-Gautier





## 1. Data and shortages trends








## Evolution of declared shortages

#### **Declared shortages 2014-2022**





Effective shortage: no units of VMPs available in the distribution channel
An increase is noted in 2020 / 2022 whereas the declarations were relatively stable before.








## Shortages and therapeutics classes

#### Categories of VMPs 2014-2022 (622 cases)






The declarations of antibiotic shortages (20%) come just after those of vaccines, but are generally not considered as critical so far because alternatives are usually still available







## Origine of shortages





#### 1. Delay

API supply, manufacturing, sub-contractors

#### 2. API supply

GMP certificates, export restrictions, lack of suppliers

#### 1. Quality issue

Impact on batch release








## Evolution of critical shortages

## Number of critical shortages communications published in the Anses website





Critical shortage: potential risk for public health or animal health


A great increase is observed in 2022, essentially due to critical shortages of vaccines.







## Critical shortages





Injectable pharmaceutical form has the most important critical shortages.

- Vaccines: 53%

Critical as few alternative available

- Antiparasitics : 9%

- Antibiotics : 5%







## 2 Shortages management









### Shortages management

#### Working group

- Octobre 2017
- multiskateholders : veterinarians, wholesalers, MAHs

#### Legal obligation

- Declaration of effective and potential shortage by MAHs: online application
- Assessment by the competent authority, search of alternatives
- Publication of critical shortages on the agency website





- •2018-2021
- •Good practices in 2018:
- •definition of a critical VMP shortage
- •roles of each actor (Agency, pharmaceutical company, wholesale distributor, veterinarians)







 Use VMPs authorised in another MS • Import from Third countries • Exceptional temporary use of unauthorised product Cascade use • Batch release approved even whitout MA specifications if no health impact • Extension of peremption • Exemption of CEP certificates in specific cases **Exemptions** • Publication of critical shortages on our website Information of alternatives





## Thank you